The present invention relates to GFRAL antagonistic antibodies having improved affinity and uses thereof, and more specifically, the present invention relates to anti-GFRAL antibodies having improved affinity or antigen-binding fragments thereof, comprising a heavy chain CDR and a light chain CDR of specific sequences. The anti-GFRAL antibody having improved affinity exhibits a higher binding capacity to GFRAL protein than a conventional anti-GFRAL antibody, and thus is expected to be effectively used for improving or treating cancer-related anorexia or cachexia syndrome and side effects of chemotherapy anti-cancer drugs.
